(Q38463163)

English

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

scientific article published on 05 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pierre Laurent-Puig

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jean-Baptiste Bachet

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Mohammed Bennamoun

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

M Mabro

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

B Chibaudel

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

C Tournigand

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

P Artru

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

S Nguyen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

C Ebenezer

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

N Aissat

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

A de Gramont

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

GERCOR

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

F Penault-Llorca

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

5 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

412-419

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23041588%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Therapeutic strategy in unresectable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS465

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38463163&oldid=1566598914"